Age and association of kidney measures with mortality and end-stage renal disease

JAMA

Volumn 308, Issue 22, 2012, Pages 2349-2360

  Hallan, Stein I ^a,b   Matsushita, Kunihiro ^c   Sang, Yingying ^c   Mahmoodi, Bakhtawar K ^c,d   Black, Corri ^e   Ishani, Areef ^f   Kleefstra, Nanne ^d,g   Naimark, David ^h   Roderick, Paul ⁱ   Tonelli, Marcello ^j   Wetzels, Jack F M ^k   Astor, Brad C ^l   Gansevoort, Ron T ^d   Levin, Adeera ^m   Wen, Chi Pang ^n,o   Coresh, Josef ^c  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f UNIVERSITY OF MINNESOTA   (United States)

^g ISALA HOSPITAL   (Netherlands)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j UNIVERSITY OF ALBERTA   (Canada)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^o CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN;

ADULT; AGE; AGED; ALBUMINURIA; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYNDROME DELINEATION;

EID: 84870948183     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.16817     Document Type: Article

References (86)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease. Am J Kidney Dis. 2002;39(2)(suppl 1):S1-S266.
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047.
3. Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17(8):2275-2284.
4. Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD. Am J Kidney Dis. 2008;51(3):373-384.
5. Gansevoort RT, de Jong PE. The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol. 2009;20(3):465-468.
6. Hallan SI, Ritz E, Lydersen S, et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009;20(5):1069- 1077.
7. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease. Kidney Int. 2011;80(1):17-28.
8. Perk J, De Backer G, Gohlke H, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). Eur Heart J. 2012;33(13):1635-1701.
9. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289(19):2560-2572.
10. O'Hare AM, Hailpern SM, Pavkov ME, et al. Prognostic implications of the urinary albumin to creatinine ratio in veterans of differentages with diabetes. Arch Intern Med. 2010;170(11):930-936.
11. Muntner P, Bowling CB, Gao L, et al. Age-specific association of reducede stimated glomerular filtration rate and albuminuria with all-cause mortality. Clin J Am Soc Nephrol. 2011;6(9):2200-2207.
12. Winearls CG, Glassock RJ. Classification of chronic kidney disease in the elderly. Nephron Clin Pract. 2011;119(suppl 1):c2-c4.
13. O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007;18(10):2758-2765.
14. Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney. Kidney Int. 2012;82(3):270-277.
15. Gansevoort RT, Matsushita K, van der Velde M, et al; CKD-PC. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. Kidney Int. 2011;80(1):93-104.
16. Matsushita K, van der Velde M, Astor BC, et al; CKD-PC. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts. Lancet. 2010;375(9731):2073-2081.
17. van der Velde M, Matsushita K, Coresh J, et al; CKD-PC. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. Kidney Int. 2011;79(12):1341-1352.
18. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
19. Matsushita K, Mahmoodi BK, Woodward M, et al; CKD-PC. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307(18):1941-1951.
20. Levey AS, Coresh J, Greene T, et al; CKD-EPI. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766-772.
21. Thompson S, Kaptoge S, White I, et al; Emerging Risk Factors Collaboration. Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. Int J Epidemiol. 2010;39(5):1345-1359.
22. Mitsuhashi H, Yatsuya H, Matsushita K, et al. Uric acid and left ventricular hypertrophy in Japanese men. Circ J. 2009;73(4):667-672.
23. Hemmelgarn BR, Clement F, Manns BJ, et al. Overview of the Alberta Kidney Disease Network. BMC Nephrol. 2009;10:30.
24. Matsushita K, Selvin E, Bash LD, et al. Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol. 2009;20(12):2617-2624.
25. White SL, Polkinghorne KR, Atkins RC, Chadban SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations. Am J Kidney Dis. 2010;55(4):660-670.
26. Shankar A, Klein R, Klein BE. The association amongsmoking, heavy drinking, and chronic kidney disease. Am J Epidemiol. 2006;164(3):263-271.
27. Zhang L, Zuo L, Xu G, et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant. 2007;22(4):1093-1099.
28. Shlipak MG, Katz R, Kestenbaum B, et al. Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. Am J Nephrol. 2009;30(3):171-178.
29. Shimizu Y, Maeda K, Imano H, et al. Chronic kidney disease and drinking status in relation to risks of stroke and its subtypes. Stroke. 2011;42(9):2531-2537.
30. Jafar TH, Qadri Z, Hashmi S. Prevalence of microalbuminuria and associated electrocardiographic abnormalities in an Indo-Asian population. Nephrol Dial Transplant. 2009;24(7):2111-2116.
31. Zhang QL, Koenig W, Raum E, et al. Epidemiology of chronic kidney disease. Prev Med. 2009;48(2):122-127.
32. Parikh NI, Hwang S-J, Larson MG, et al. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol. 2008;102(1):47-53.
33. Cirillo M, Lanti MP, Menotti A, et al. Definition of kidney dysfunction as a cardiovascular risk factor. Arch Intern Med. 2008;168(6):617-624.
34. Noda H, Iso H, Irie F, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage. Circulation. 2009;119(16):2136-2145.
35. Bui AL, Katz R, Kestenbaum B, et al. Cystatin C and carotid intima-media thickness in asymptomatic adults. Am J Kidney Dis. 2009;53(3):389-398.
36. Roderick PJ, Atkins RJ, Smeeth L, et al. CKD and mortality risk in older people. Am J Kidney Dis. 2009;53(6):950-960.
37. Astor BC, Hallan SI, Miller ER III, et al. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(10):1226-1234.
38. Nakayama M, Metoki H, Terawaki H, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population - the Ohasama study. Nephrol Dial Transplant. 2007;22(7):1910-1915.
39. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63(4):1468-1474.
40. Iseki K, Kohagura K, Sakima A, et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res. 2007;30(1):55-62.
41. Hillege HL, Fidler V, Diercks GF, et al; PREVEND Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777-1782.
42. Jassal SK, Kritz-Silverstein D, Barrett-Connor E. A prospective study of albuminuria and cognitive function in older adults. Am J Epidemiol. 2010;171(3):277-286.
43. Howard VJ, Cushman M, Pulley L, et al. The Reasons for Geographic and Racial Differences in Stroke Study. Neuroepidemiology. 2005;25(3):135-143.
44. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence. Stroke. 2009;40(11):3422-3427.
45. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease. Lancet. 2008;371(9631):2173-2182.
46. Ingelsson E, Sundström J, Lind L, et al. Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. Eur Heart J. 2007;28(14):1739-1745.
47. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial). Lancet. 2007;370(9590):829-840.
48. Tonelli M, Jose P, Curhan G, et al; CARE Trial Investigators. Proteinuria, impaired kidney function,and adverse outcomes in people with coronary disease. BMJ. 2006;332(7555):1426.
49. Jurkovitz CT, Qiu Y, Wang C, et al. The Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008;51(4)(suppl 2):S3-S12.
50. Lee BJ, Forbes K. The role of specialists in managing the health of populations with chronic illness. BMJ. 2009;339:b2395.
51. Ishani A, Grandits GA, Grimm RH, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the Multiple Risk Factor Intervention Trial. J Am Soc Nephrol. 2006;17(5):1444-1452.
52. Pavkov ME, Knowler WC, Hanson RL, et al. Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes. Am J Kidney Dis. 2008;51(5):759-766.
53. Bilo HJ, Logtenberg SJ, Joosten H, et al. Modification of diet in renal disease and Cockcroft-Gault formulas do not predict mortality (ZODIAC-6). Diabet Med. 2009;26(5):478-482.
54. Wright JT Jr, Bakris G, Greene T, et al; AASK Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA. 2002;288(19):2421-2431.
55. Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis. 2008;52(4):661-671.
56. Landray MJ, Thambyrajah J, McGlynn FJ, et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis. 2001;38(3):537-546.
57. Perkins RM, Bucaloiu ID, Kirchner HL, et al. GFR decline and mortality risk among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(8):1879-1886.
58. Marks A, Black C, Fluck N, et al. Translating chronic kidney disease epidemiology into patient care - the individual/public health risk paradox [published online April 24, 2012]. Nephrol Dial Transplant. doi:10.1093/ndt/ gfr746.
59. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659-663.
60. van Zuilen AD, Blankestijn PJ, van Buren M, et al. Nurse practitioners improve quality of care in chronic kidney disease. Neth J Med. 2011;69(11):517-526.
61. Klahr S, Levey AS, Beck GJ, et al; MDRD Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330(13):877-884.
62. Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000;11(1):105-115.
63. Moranne O, Froissart M, Rossert J, et al; Nephro-Test Study Group. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2009;20(1):164-171.
64. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
65. Jorsal A, Tarnow L, Frystyk J, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int. 2008;74(5):649-654.
66. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553-1559.
67. Delanaye P, Weekers L, Dubois BE, et al. Outcome of the living kidney donor. Nephrol Dial Transplant. 2012;27(1):41-50.
68. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores. JAMA. 2001;286(2):180-187.
69. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA. 1994;272(17):1335-1340.
70. Martín-Ponce E, Santolaria F, Alemán-Valls MR, et al. Factors involved in the paradox of reverse epidemiology. Clin Nutr. 2010;29(4):501-506.
71. Rifkin DE, Katz R, Chonchol M, et al. Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant. 2010;25(5):1560-1567.
72. Hallan SI, Astor BC, Romundstad S, et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals. Arch Intern Med. 2007;167(22):2490-2496.
73. Foley RN, Wang C, Snyder JJ, et al. Kidney function and risk triage in adults. Kidney Int. 2011;79(1):99-111.
74. Conway B, Webster A, Ramsay G, et al. Predicting mortality and uptake of renal replacement therapy in patients with stage 4 chronic kidney disease. Nephrol Dial Transplant. 2009;24(6):1930-1937.
75. Van Pottelbergh G, Bartholomeeusen S, Buntinx F, Degryse J. The evolution of renal function and the incidence of end-stage renal disease in patients aged ≥50 years. Nephrol Dial Transplant. 2012;27(6):2297-2303.
76. National Institute for Health and Clinical Excellence. Clinical Guideline 73: Chronic Kidney Disease: Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care. 2008. http://www.nice.org.uk/CG073fullguideline. Accessed April 12, 2012.
77. Hemmelgarn BR, James MT, Manns BJ, et al; Alberta Kidney Disease Network. Rates of treated and untreated kidney failure in older vs younger adults. JAMA. 2012;307(23):2507-2515.
78. Poggio ED, Rule AD. A critical evaluation of chronic kidney disease - should isolated reduced estimated glomerular filtration rate be considered a "disease"? Nephrol Dial Transplant. 2009;24(3):698-700.
79. Prakash S, O'Hare AM. Interaction of aging and chronic kidney disease. Semin Nephrol. 2009;29(5):497-503.
80. Cao JJ, Biggs ML, Barzilay J, et al. Cardiovascular and mortality risk prediction and stratification using urinary albumin excretion in older adults ages 68-102: the Cardiovascular Health Study. Atherosclerosis. 2008;197(2):806-813.
81. Chang A, Kramer H. Should eGFR and albuminuria be added to the Framingham Risk Score?. Nephron Clin Pract. 2011;119(2):c171-c177.
82. Clase CM, Gao P, Tobe SW, et al; ONTARGET and TRANSCEND. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk. Ann Intern Med. 2011;154(5):310-318.
83. Ito H, Pacold IV, Durazo-Arvizu R, et al. The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals. Am J Epidemiol. 2011;174(8):949-957.
84. Bowling CB, Inker LA, Gutiérrez OM, et al. Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. Clin J Am Soc Nephrol. 2011;6(12):2822-2828.
85. Kilbride HS, Stevens PE, Eaglestone G, et al. Accuracy of the MDRD (Modification of Diet in Renal Disease) Study and CKD-EPI (CKD Epidemiology Collaboration) Equations for estimation of GFR in the elderly [published online August 11, 2012]. Am J Kidney Dis. doi:10.1053/j.ajkd.2012.06.016.
86. Earley A, Miskulin D, Lamb EJ, et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization. Ann Intern Med. 2012;156(11):785-795.